Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study

Graphical abstract Efficacy of Combination Pembrolizumab, Bevacizumab, Cyclophosphamide PROC treatment in community practice. Study overview.

• Publication year

  2025

• Venue

  Gynecologic Oncology Reports

• Publication date

  2025-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.gore.2025.101793PMID 40687916PMCID 12271593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2025

  2025cited by this paper
• Disparities in Cancer Stage Outcomes by Catchment Areas for a Comprehensive Cancer Center

  2024cited by this paper
• Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

  2023cited by this paper
• Overcoming the challenges of drug development in platinum-resistant ovarian cancer

  2023cited by this paper
• Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer

  2023influential reference
• Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

  2023cited by this paper
• Cancer statistics, 2022

  2022cited by this paper
• Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.

  2020cited by this paper
• The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation

  2020cited by this paper
• Ovarian cancer: Current status and strategies for improving therapeutic outcomes

  2019influential reference
• VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors

  2016cited by this paper
• Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

  2014cited by this paper
• Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.

  2014cited by this paper
• Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System

  2014cited by this paper
• The Hallmarks of Cancer Review

  2000cited by this paper
• Cáncer

  1939cited by this paper

• No citing papers are available for this paper.